TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06134531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR001
Description: Dose Level 1: 0.5 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 1 cycle~Dose Level 2: 2 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 3: 6 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 4: 10 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 5: 15 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle~Dose Level 6: 20 mg/kg Intravenously (IV) Frequency: administered on Day 1 of each cycle (every 3 weeks), 4 cycle
Study: NCT04676360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Belantamab mafodotin will be administered intravenously at calculated dose on day 1 of each 21-day cycle.
Study: NCT05901961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Whitfield and Zinc oxide nanoparticles solution
Description: The patient will receive 60 mL of combined Whitfield and Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
Study: NCT05460247

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Participants will receive a diet supplemented by the above protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Participants will receive a diet supplemented by the above protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Participants will receive a diet supplemented by the above protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Participants will receive a diet supplemented by the above protein
Study: NCT05436288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)
Description: KIO-201 is a stand-alone drug therapy that acts as a barrier that minimizes mechanical lid friction and mechanically protects the ocular surface thereby reducing repeat injury and providing an environment that enables the body to repair the ocular surface whether the corneal epithelial defects are large or small.
Study: NCT05817604

Intervention type: RADIATION
Intervention: SBRT
Description: Tumors ≤ 4cm: Single SBRT 26Gy dose or Multifraction SBRT dose 14Gyx3 fraction-squeme.~Tumors ≥ 4cm: Multifraction SBRT dose 14Gyx3 or 9Gyx5 fraction-squeme.
Study: NCT04616521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for moderate-to-advanced stage PD. The targets used in this study are STN and GPi, which are widely accepted and used for symptom control in PD. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the movement disorder specialist.
Study: NCT05985980

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise Treadmill Test (ETT)
Description: The study population consists of premenopausal women who applied to the outpatient clinic with chest pain. ETT is ordered as a routine diagnostic workup. Two ETTs are performed on each participant. The early follicular phase ETT is planned on the 3rd day of menstrual bleeding, while the menstrual bleeding continues. The late follicular phase ETT is planned on the 3rd day after the menstrual bleeding ends. Hormone levels are measured before each ETT to ascertain the phase of the menstrual cycle.
Study: NCT05573282

Intervention type: OTHER
Intervention: Regorafenib combine with ICIs
Description: Regorafenib: 80mg/day, PO, QD, d1～d21, Q4W ICIs: 200mg/day, IV, d1,Q3W
Study: NCT03645447

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Taste test
Description: A pseudo-randomised series of taste solutions are presented to the participant for identification as sugar or water, in order to establish their taste threshold.
Study: NCT05308940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB001
Description: once-daily subcutaneous injection, on Day 1 in SAD stage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB001
Description: once-daily subcutaneous injection, on Days 1-7 in MAD stage
Study: NCT05422885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 100 mg for 2 consecutive days, every two weeks for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: Quercetin 1,250 mg for 2 consecutive days, every two weeks for 12 weeks
Study: NCT05308940

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once-daily subcutaneous injection, on Day 1 in SAD stage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once-daily subcutaneous injection, on Days 1-7 in MAD stage
Study: NCT05347004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809
Study: NCT05084651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaplacide
Description: Treatment A/Period 1: 400 mg (4 x 100 mg tablets) at Hour 0 on Day 1 Treatment B/Period 2: 400 mg (4 x 100 mg tablets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lumefantrine
Description: Treatment A/Period 1: 480 mg (2 x 240 mg sachets) at Hour 0 on Day 1 Treatment B/Period 2: 480 mg (2 x 240 mg sachets) at Hour 0, approximately 2 hours after itraconazole dosing, on Day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg (20 mL of 10 mg/mL oral solution) q.d. on Days 1 to 18
Study: NCT06281847

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CCTx-001
Description: Frozen CAR T-cells suspensions in media containing dimethyl sulfoxide (DMSO)
Study: NCT06158386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide combined with Linperlisib
Description: Specified dose on specified days: Cedarbenzamide (C) 20mg orally twice weekly, Limplica (L) 80mg once daily, 2 weeks on 2 weeks off, Repeat on day 28.
Study: NCT04729881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Rehabiliation Group
Description: Transcutaneous Electrical Nerve Stimulation, Ultrasound and Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spesific Exercise Group
Description: Cervical stretching exercise, Craniocervical flexion exercise, Neck isometric exercises, Cervical retraction exercise, Scapular retraction exercise, Modified push-up plus exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: No intervention will be aplied
Study: NCT04957953

Intervention type: OTHER
Intervention: Patient's consent
Description: Primary enrolment will be carried out at the time of vaccination at the main vaccination sites, with the patient's consent. The agreement form filled in online includes the surname, first name, month and year of birth. This form serves as an agreement to participate in the study.

Intervention type: OTHER
Intervention: Inclusion form
Description: This form includes the date of the last menstrual period, vaccination data (type of vaccine, date of vaccination, 1st or 2nd injection, etc.), socio-demographic data of the pregnant woman, medical and surgical history, gynaecological and obstetrical history, a description of the current pregnancy, and the medication taken by the patient during her pregnancy....~A link to complete this form (with the unique identifier) will be sent to each woman included who has given her consent to participate.

Intervention type: OTHER
Intervention: Adverse reaction report form.
Description: One month after each injection of the vaccine, information will be collected on any vaccination-related adverse reactions that may impact the pregnancy (fever, hypertension, etc.) or on the onset of a Covid-19 infection,

Intervention type: DIAGNOSTIC_TEST
Intervention: Follow-up report form.
Description: In the 2 months following the expected delivery date, information will be collected on the outcome of the pregnancy (delivery, spontaneous abortion, etc.) and maternal clinical signs (pre-eclampsia, gestational hypertension, gestational diabetes, etc.). Before sending the link to this form, information will be sent to the second holder of parental authority. In the absence of opposition, data on the newborn will be collected (sex, height, weight, head circumference, Apgar, malformation, neonatal pathology, etc.)
Study: NCT06458491

Intervention type: DEVICE
Intervention: Evolution of urinary symptoms
Description: Evolution of urinary symptoms 3 months after the start of use of the TENSI+ device
Study: NCT06627140

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic procedures
Description: Self- and parent-report on behavioral/emotional symptoms and assessment of cognitive functioning

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic procedures
Description: Self- and parent-report on behavioral/emotional symptoms and assessment of cognitive functioning

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic procedures
Description: Self- and parent-report on behavioral/emotional symptoms and assessment of cognitive functioning
Study: NCT06626529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided mindfulness meditation
Description: Watching a video of a guided mindfulness meditation include paying attention to the breath, promoting natural breathing without force; body scan, directing awareness from the head down to the toes, allowing tension to release in each area. The intervention emphasizes observing sensations without judgment, fostering a state of relaxed awareness.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Scenery video
Description: Watching a ten-minute video of calming music and images
Study: NCT04949334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dofin Breathing Strength Builder
Description: If the patient's condition is stable, respiratory muscle training will be performed under Dofin Breathing Strength Builder 7 days after stroke. The patient will receive respiratory muscle training by repetition of 30 times, two courses per day, x 7 days, for three weeks.~The initial load was set at 30% of the participants' maximal baseline strength and increased weekly at intervals of 2 cmH2O.
Study: NCT04842825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Er Zhi Wan combined with Si Wu Tang
Description: The TCM medicines used will be Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 20 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 12 g, Radix Yam 20 g. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening, for 10-15 days. According to follicular development and endometrial growth monitored by ultrasound, the herbs will be changed to Curculus 10 g, Xianling spleen 15 g, Morinda officinalis 15 g, Cuscutae 20 g, Amethyst 15 g, Rehmannia 20 g, Angelica 15 g, Chuanxiong 10 g，which will be taken for 10-15days.~After ET, the treatment group will continue to take Chinese herbal medicine, changing to Cuscuta 15 g, Sambucus 15 g, Chuan Guan Gong 10 g, Agaricus 9 g, Shu Di 15 g, Angelica 10 g, Bai Shao 12 g for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Follitropin Alfa 、Fructose 、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder
Description: The control group will be treated with conventional Western medicine（The specific drug dose is determined according to the individual level of patients）
Study: NCT06448767

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multispecies probiotics
Description: Multispecies probiotics consisting of Bacillus subtilis W201, Bifidobacterium infantis W17, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus rhamnosus W140, Lactococcus lactis W19, Propionibacterium freudenreichii W200 at a dose of 5x10\^9 Colony Forming Units (CFU), once daily, orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in taste, smell and color to the multispecies probiotics.
Study: NCT06699433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual standardized patients (VSPs)
Description: Virtual standardized patients (VSPs), utilizing internet and virtual simulation technology, emulate patients with specific disease characteristics and clinical manifestations. With advantages in safety, flexibility, convenience, and efficiency, VSPs are used in medical education, clinical reasoning training, and licensure examinations. Doctors will interact with VSPs to conduct clinical simulations and training, including consultations, physical examinations, auxiliary examinations, and treatment decision-making, to enhance their capabilities for managing common pediatric diseases

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case teaching manuals
Description: Doctors will use case teaching manuals to enhance their capabilities for managing common pediatric diseases

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case teaching videos
Description: Doctors will use case teaching videos to enhance their capabilities for managing common pediatric diseases
Study: NCT05261802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Descriptive Intervention
Description: A trained facilitator, supported by Career and Family Coaches, leads every HMRE parenting workshop for adults via multiple delivery models: in recurring weekly workshops (2 hours each workshop for 7 weeks) and intensive weekend retreats (totaling 16 hours). Additionally, AVANCE offers the weekly workshops either virtually via Zoom or in-person. All workshop models were offered to program participants who were able to choose whether the weekly (either in-person or virtually) or the weekend (in-person only) format worked best for them. Curriculum content is consistent across all delivery methods and target hours for all participants is 14 hours.
Study: NCT05558501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild Intermittent Hypoxia
Description: The MIH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve two-minute episodes of hypoxia \[partial pressure of end-tidal oxygen (PETO2)= 50 mmHg\]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The final episode will be followed by a 30-minute end-recovery period. The partial pressure of end-tidal carbon dioxide (PETCO2) will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol. To rapidly induce a PETO2 of 50 mmHg participants will inspire a gas mixture comprised of 8 % oxygen and 92 % nitrogen from a non-diffusible bag. To maintain PETO2 (i.e. 50 mmHg) and PETCO2 (i.e. 2 mmHg above baseline) at the desired levels supplemental oxygen and carbon dioxide will be added to the inspiratory line from the output of a flow meter device that receives inputs from tanks of 100 % oxygen and 100 % carbon dioxide.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham MIH
Description: During sham MIH the participants will be exposed to compressed air (the equivalent of room air).
Study: NCT05377931

Intervention type: DIAGNOSTIC_TEST
Intervention: Changes in heart pulse rate
Description: Measuring heart pulse rate using a wrest smart watch.

Intervention type: DIAGNOSTIC_TEST
Intervention: Changes in heart pulse rate
Description: Measuring heart pulse rate using a wrest smart watch.

Intervention type: DIAGNOSTIC_TEST
Intervention: Changes in heart pulse rate
Description: Measuring heart pulse rate using a wrest smart watch.

Intervention type: DIAGNOSTIC_TEST
Intervention: Changes in eye strain
Description: Changes in Accommodation measured by auto refractometer before and after mobile battle ground gaming.

Intervention type: DIAGNOSTIC_TEST
Intervention: Changes in eye strain
Description: Changes in Accommodation measured by auto refractometer before and after mobile battle ground gaming.

Intervention type: DIAGNOSTIC_TEST
Intervention: Changes in eye strain
Description: Changes in Accommodation measured by auto refractometer before and after mobile battle ground gaming.
Study: NCT04311320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Resource Oxygen Blender
Description: The device that is being evaluated is a novel low-cost, high access oxygen blender designed to be used in the World Health Organization bCPAP design. It functions by utilizing the Venturi effect, whereby a narrow jet of one fluid (i.e. oxygen) creates a suction effect and entrains surrounding ambient fluid (i.e. room air) into the jet, effectively creating a mixed solution of both fluids. The cost of materials amounts to approximately 1.40 U.S.D. The average time it takes to build a blender and incorporate it into a bCPAP circuit for a new user is approximately 16 minutes. The materials can all be found in a standard hospital, namely 3cc syringes with rubber stops and a 22 gauge hypodermic needle.
Study: NCT05262985

Intervention type: DRUG
Group type: OTHER
Intervention: Durvalumab
Description: In patients with advanced treatment naive LCNEC, treatment with Durvalumab+ Cisplatin/Carboplatin+Etoposide
Study: NCT04119986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug coated balloon
Description: Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for \>30 seconds.

Intervention type: DEVICE
Group type: OTHER
Intervention: drug eluted stent
Description: with regular techniques
Study: NCT05500703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injectable Solution
Description: continuous pump of 1.5ug / kg / h Dexmedetomidine 15min before anesthesia induction, continuous infusion for 30min after anesthesia induction, and then nuclear magnetic scanning was started.
Study: NCT05219786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appendicitis Decision Support Tool
Description: Viewing of a decision support tool.
Study: NCT05500703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: the equivalent Sodium Chloride 0.9% Inj was continuously pumped before anesthesia induction, induced by opioids for 15min, and intraoperative fMRI scanning was started after continuous infusion for 30min.
Study: NCT06219044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic endometrioma laser vaporization
Description: laser vaporization of ovarian endometrioma using a DWLS diode laser during a laparoscopy
Study: NCT05174741

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Chest Physiotherapy
Description: Diaphragmatic Breathing exercise 15 repetition ACBT \*3 sets/session\*TD Walk (10-15 minutes) \* BD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training Group
Description: Supervised Conventional Chest Physiotherapy + Aerobic training~Aerobic training on cycle ergometer:~between 50% and 70% Vo2max, perceived exertion up to 11 on Borg scale 20-30 min/session/day
Study: NCT05219786

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Infographic
Description: Viewing of a standardized infographic
Study: NCT06031610

Intervention type: PROCEDURE
Intervention: carotid artery stenting
Description: Patients were monitored for at least 24 h after surgery, with control for hyperperfusion syndrome, dual antiplatelet therapy was continued for 4-6 weeks, and the postoperative patients have the final residual stenosis of less than 30%, thrombolysis in Myocardial Infarction (TIMI) grade 3, and no dissection or thrombosis. Any surgery-related complications were recorded.

Intervention type: DRUG
Intervention: drug therapy
Description: Carotid artery stenosis requires taking antiplatelet aggregation drugs and statin lipid-lowering drugs. It can inhibit platelet aggregation, stabilize plaque, reduce vascular inflammatory factors, and prevent further development of atherosclerosis.
Study: NCT06639958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training and Education
Description: Undergo training for prompting and supervising 6MP
Study: NCT06229236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Navigator
Description: Participants in the Diabetes Navigator (DN) arm will receive support from a trained navigator to help them improve progression (improving use/optimization) in use of advanced diabetes technology. The Diabetes Navigator will engage with participants immediately after randomization, throughout the duration of study, using a predefined toolkit, educational resources and interventions to assist them in optimizing use of advanced diabetes technology.
Study: NCT05171179

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast Reconstruction (Mammaplasty)
Description: Breast Reconstruction (mammaplasty) surgery with implant-based tissue expander

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Reconstruction (Mammaplasty)
Description: Breast Reconstruction (mammaplasty) surgery with implant-based tissue expander

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Breast Reconstruction (Mammaplasty)
Description: Breast Reconstruction (mammaplasty) surgery with implant-based tissue expander
Study: NCT05024942

Intervention type: PROCEDURE
Intervention: Transfemoral TAVR (Transcatheter aortic valve replacement)
Description: Transfemoral transcatheter aortic valve replacement (TAVR) is a minimally invasive heart procedure to replace a narrowed aortic valve that fails to open properly (aortic valve stenosis) through an incision in the groin. All FDA approved transcatheter aortic prosthesys are allowed.